Perrigo (PRGO) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.42%. A quarter ago, it was expected that this drug company would post earnings of $0.24 per share when it actually produced earnings of $0.29, delivering a surprise of 20.83%.Over the last four quarters, the company has ...

EXHIBIT 99.1 Perrigo Reports Second Quarter 2024 Financial Results From Continuing Operations Delivered Adjusted Diluted Earnings Per Share Results as Expected; Reaffirm Fiscal 2024 Adjusted Diluted EPS Outlook Progressing One Perrigo Blueprint: On Target to Deliver Project Energize Goals; Enhancing Capabilities; Completed Divestment of HRA Pharma Rare Diseases Business on July 10, 2024 Second Quarter 2024 Highlights: 1 • Net sales of $1.1 billion declined 10.7% versus the prior year quarter. Organic net sa ...

Core Insights - The company reported a net sales decline of 10.7% year-over-year for Q2 2024, totaling $1.1 billion, primarily due to lower infant formula sales and reduced demand in seasonal categories [2][4][12] - Adjusted diluted earnings per share (EPS) for Q2 2024 was $0.53, down from $0.63 in the prior year, reflecting a decline attributed to prior year tax benefits and the impact of infant formula sales [2][3][4] - The company reaffirmed its fiscal 2024 adjusted diluted EPS outlook of $2.50 to $2.65, despite updating its organic net sales growth forecast to a decline of 3% to 1% [4][13] Financial Performance - Q2 2024 net sales were $1.1 billion, a decrease of $128 million or 10.7% compared to the prior year, with organic net sales down 9.1% [2][8] - Gross margin improved to 37.0%, a 120 basis points increase from the previous year, while adjusted gross margin expanded to 40.6%, up 190 basis points [2][8] - The company reported an operating loss of $27 million for Q2 2024, compared to an income of $57 million in the prior year, while adjusted operating income increased by 1.5% to $139 million [2][8] Segment Performance - Consumer Self-Care Americas (CSCA) net sales decreased by 15.5% to $634 million, primarily due to lower infant formula sales and reduced demand in seasonal categories [10][11] - Consumer Self-Care International (CSCI) reported a net sales decline of 2.5% to $431 million, with organic growth of 1.0% offset by product line exits and foreign currency impacts [11][12] - Adjusted operating income for CSCI increased by 29.5% to $91 million, driven by lower advertising investments and cost savings from Project Energize [11][12] Strategic Initiatives - The company is implementing Project Energize, a three-year program aimed at enhancing organizational agility and driving efficiency, expected to yield annualized pre-tax savings of $140 million to $170 million by 2026 [6][12] - The divestment of HRA Pharma Rare Diseases business was completed on July 10, 2024, generating upfront proceeds of $205 million [2][12] - The company is focusing on improving quality control and production capabilities, with expectations of a profit recovery in the second half of 2024 [5][12]

DUBLIN, Aug. 1, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of Consumer Self-Care Products, today announced that its Board of Directors declared a quarterly dividend of $0.276 per share, payable on September 17, 2024, to shareholders of record on August 30, 2024.About Perrigo Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consum ...

DUBLIN, July 31, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Canaccord Genuity 44th Annual Growth Conference, on Wednesday, August 14 at 3:30 PM EDT. Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts.About Perrigo Perrigo Company plc (NYSE: PRGO) is a leading provi ...

Perrigo Company plc (PRGO) is scheduled to report second-quarter 2024 numbers on Aug 2, before the opening bell. In the last reported quarter, the company posted an earnings surprise of 20.83%.Let’s see how things have shaped up for this announcement.Factors at PlayThe Zacks Consensus Estimate for Perrigo’s total revenues is pegged at around $1.13 billion, while the same for earnings stands at 48 cents per share. Both metrics indicate a decline from the year-ago quarter’s levels.Perrigo reports its results ...

The market expects Perrigo (PRGO) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on August 2, 2024, might help the stock move higher if these key numbers are better t ...

DUBLIN, July 19, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its second quarter 2024 financial results on Friday, August 2, 2024, and host a conference call beginning at 8:30 A.M. (EST).The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-664-6383, In ...

Core Viewpoint - Perrigo Company plc has completed the divestment of its HRA Pharma Rare Diseases business to Esteve Healthcare for a total consideration of up to €275 million, which includes an upfront cash payment of €190 million and potential earnout payments of up to €85 million based on sales milestones [1] Financial Impact - The HRA Pharma Rare Diseases business generated net sales of approximately €50 million and adjusted EBITDA of approximately €20 million in 2023 [1] - The proceeds from the divestment are expected to be redeployed for debt repayment [1] Transaction Details - The total consideration for the divestment is structured as an upfront cash payment of €190 million, subject to customary net debt and working capital adjustments, and up to €85 million in potential earnout payments [1] - The impact of this transaction was included in the Company's previously issued 2024 outlook [1]

SEATTLE, June 24, 2024 (GLOBE NEWSWIRE) -- UNITED STATES DISTRICT COURTDISTRICT OF NEW JERSEY ROOFER’S PENSION FUND, on behalf ofitself and all others similarly situated,                        Plaintiff,        v.JOSEPH C. PAPA, et al.,                        DefendantsCase No. 1:16-cv-02805-RMB-LDWCLASS ACTION SUMMARY NOTICE OF (I) PROPOSED SETTLEMENTAND PLAN OF ALLOCATION; (II) SETTLEMENT HEARING; AND(III) MOTION FOR ATTORNEYS’ FEES AND LITIGATION EXPENSES To:(1) All persons who purchased Perrigo Compan ...